Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Expert Rev Clin Pharmacol. 2024 Feb 12:1-10. doi: 10.1080/17512433.2024.2312256. Online ahead of print.ABSTRACTINTRODUCTION: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or...
Source: Pharmacological Reviews - February 12, 2024 Category: Drugs & Pharmacology Authors: Anna Sofie Buhl Rasmussen Christen Lykkegaard Andersen Allan Weimann Tianwu Yang Camille Tron Virginie Gandemer Kim Dalhoff Cecilie Utke Rank Kjeld Schmiegelow Source Type: research
Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Expert Rev Clin Pharmacol. 2024 Feb 12:1-10. doi: 10.1080/17512433.2024.2312256. Online ahead of print.ABSTRACTINTRODUCTION: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or...
Source: Expert Review of Clinical Pharmacology - February 12, 2024 Category: Drugs & Pharmacology Authors: Anna Sofie Buhl Rasmussen Christen Lykkegaard Andersen Allan Weimann Tianwu Yang Camille Tron Virginie Gandemer Kim Dalhoff Cecilie Utke Rank Kjeld Schmiegelow Source Type: research
Cancers, Vol. 16, Pages 754: The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?
li
Mohamed Yassin
Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, a...
Source: Cancers - February 12, 2024 Category: Cancer & Oncology Authors: Ibrahim Elmakaty Giuseppe Saglio Murtadha Al-Khabori Abdelrahman Elsayed Basant Elsayed Mohamed Elmarasi Ahmed Adel Elsabagh Awni Alshurafa Elrazi Ali Mohamed Yassin Tags: Review Source Type: research
Genes, Vol. 15, Pages 232: Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis
-Yebra
Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and distinct BCR::ABL1 gene transcripts. We assessed the frequencies of these transcripts in Mexico, Latin America, and worldwide. We determined the prevalence of BCR::ABL1 transcripts in CML patients and intercontinental or regional variations using specialized databases and keywords. We analyzed 34 studies from 20 countries, encompassing 5795 patients. Keyword-based searches in specialized databases guided data collection. ANOVA was employed for transcript distribution analysis. The b3a2 transcript was most prevalent globally, follow...
Source: Genes - February 12, 2024 Category: Genetics & Stem Cells Authors: Pablo Romero-Morelos Ana Lilia Gonz ález-Yebra Daniela Mu ñoz-López Elia Lara-Lona Beatriz Gonz ález-Yebra Tags: Article Source Type: research
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia
CONCLUSION: Although BM fibrosis seems to be a crucial complication of CML with a poor prognosis, it can be reversed via TKI treatment which may result in improved survival. It might be considered to check the BM for this complication on a regular basis during therapies to test its prognostic influence in CML patients in prospective controlled trials. Further studies focused on this issue are required to utilize BM fibrosis as a candidate prognostic factor.PMID:38342726 | DOI:10.1016/j.clml.2023.12.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 11, 2024 Category: Cancer & Oncology Authors: Mehmet Sezgin Pepeler Mesut T ıglıoglu Simten Dagdas Esra Ozhamamc ıoglu Unsal Han Aynur Albayrak M ürüvvet Seda Aydın G ülten Korkmaz Merve Pamukcuo ğlu Funda Ceran Murat Albayrak G ülsüm Ozet Source Type: research
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia
CONCLUSION: Although BM fibrosis seems to be a crucial complication of CML with a poor prognosis, it can be reversed via TKI treatment which may result in improved survival. It might be considered to check the BM for this complication on a regular basis during therapies to test its prognostic influence in CML patients in prospective controlled trials. Further studies focused on this issue are required to utilize BM fibrosis as a candidate prognostic factor.PMID:38342726 | DOI:10.1016/j.clml.2023.12.015 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 11, 2024 Category: Cancer & Oncology Authors: Mehmet Sezgin Pepeler Mesut T ıglıoglu Simten Dagdas Esra Ozhamamc ıoglu Unsal Han Aynur Albayrak M ürüvvet Seda Aydın G ülten Korkmaz Merve Pamukcuo ğlu Funda Ceran Murat Albayrak G ülsüm Ozet Source Type: research
BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach
AbstractPurpose of ReviewThe purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.Recent FindingsThere is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children.SummaryChronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses. Use of more specific TKI...
Source: Current Oncology Reports - February 10, 2024 Category: Cancer & Oncology Source Type: research
Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
CONCLUSION: This study highlights the hub gene and lncRNA/mRNA co-expression network as crucial elements in the context of CDA-II treatment of CML. This insight not only enriches our understanding of CDA-II's mechanism of action but also might provide valuable clues for subsequent experimental studies of CDA-II, and potentially contribute to the discovery of new therapeutic targets for CML.PMID:38325533 | DOI:10.1016/j.ygeno.2024.110806 (Source: Genomics)
Source: Genomics - February 7, 2024 Category: Genetics & Stem Cells Authors: Lei Jiang Haoyuan Hong Shulin Xiang Han Li Jianyu Ji Mei Lan Bin Luo Source Type: research
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
CONCLUSIONS: Neutralizing ISR hyperactivation could prevent or reverse ponatinib-induced cardiotoxicity. The findings that compromised ATP production potentiates GCN2-mediated ISR activation have broad implications across various cardiac diseases. Our results also highlight an unanticipated role of ponatinib in causing direct activation of a kinase target despite its role as an ATP-competitive kinase inhibitor.PMID:38323474 | DOI:10.1161/CIRCRESAHA.123.323683 (Source: Circulation Research)
Source: Circulation Research - February 7, 2024 Category: Cardiology Authors: Gege Yan Zhenbo Han Youjeong Kwon Jordan Jousma Sarath Babu Nukala Benjamin L Prosser Xiaoping Du Sandra Pinho Sang-Bing Ong Won Hee Lee Sang-Ging Ong Source Type: research
Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
CONCLUSION: This study highlights the hub gene and lncRNA/mRNA co-expression network as crucial elements in the context of CDA-II treatment of CML. This insight not only enriches our understanding of CDA-II's mechanism of action but also might provide valuable clues for subsequent experimental studies of CDA-II, and potentially contribute to the discovery of new therapeutic targets for CML.PMID:38325533 | DOI:10.1016/j.ygeno.2024.110806 (Source: Genomics)
Source: Genomics - February 7, 2024 Category: Genetics & Stem Cells Authors: Lei Jiang Haoyuan Hong Shulin Xiang Han Li Jianyu Ji Mei Lan Bin Luo Source Type: research
Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
CONCLUSION: This study highlights the hub gene and lncRNA/mRNA co-expression network as crucial elements in the context of CDA-II treatment of CML. This insight not only enriches our understanding of CDA-II's mechanism of action but also might provide valuable clues for subsequent experimental studies of CDA-II, and potentially contribute to the discovery of new therapeutic targets for CML.PMID:38325533 | DOI:10.1016/j.ygeno.2024.110806 (Source: Genomics)
Source: Genomics - February 7, 2024 Category: Genetics & Stem Cells Authors: Lei Jiang Haoyuan Hong Shulin Xiang Han Li Jianyu Ji Mei Lan Bin Luo Source Type: research
Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine
ConclusionOur case sheds light on the importance of selinexor and AZA combined therapy in the exploration of new treatment strategies for aCML. Moreover, this treatment approach offers the possibility of bridging with allo-HSCT. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 7, 2024 Category: Cancer & Oncology Source Type: research
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape
AbstractChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and the consequent BCR::ABL1 oncoprotein. In the era before the introduction of tyrosine kinase inhibitors (TKIs), the only potentially curative treatment was allogeneic hematopoietic stem cell transplantation (HSCT). Here, we present the case of a patient affected by CML who experienced a relapse 20 Â years after allogeneic HSCT. Following relapse, the patient was treated with imatinib and bosutinib, resulting in a deep molecular response and successfully discontinued treatment. Additional analysi...
Source: Annals of Hematology - February 7, 2024 Category: Hematology Source Type: research
Acute promyelocytic leukemia with < em > PML/RARA < /em > (bcr1, bcr2 and bcr3) transcripts in a pediatric patient
Oncol Lett. 2024 Jan 22;27(3):114. doi: 10.3892/ol.2024.14246. eCollection 2024 Mar.ABSTRACTPatients with acute promyelocytic leukemia (APL) exhibit the t(15;17)(q24.1;q21.2) translocation that produces the promyelocytic leukemia (PML)/retinoic acid receptor α (RARA) fusion gene. Different PML breakpoints yield three alternative molecular transcripts, bcr1, bcr2 and bcr3. The present study reports the simultaneous presence of three PML/RARA transcripts in a pediatric female patient diagnosed with APL, according to the clinical characteristics, immunophenotype and karyotype of the patient. The simultaneous presence of the ...
Source: Oncology Letters - February 2, 2024 Category: Cancer & Oncology Authors: Jennifer Santana-Hern ández Alfredo Corona-Rivera Lucero Mendoza-Maldonado Uriel Francisco Santana-Bejarano Idalid Cuero-Quezada Aurea Marquez-Mora Graciela Seraf Ãn-Saucedo Sinhue Alejandro Brukman-Jim énez Rom án Corona-Rivera Daniel Ortu ño-Sahagà Source Type: research
State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
Leukemia, Published online: 02 February 2024; doi:10.1038/s41375-024-02142-9State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia (Source: Leukemia)
Source: Leukemia - February 2, 2024 Category: Hematology Authors: David E. Frankhouser Russell C. Rockne Lisa Uechi Dandan Zhao Sergio Branciamore Denis O ’Meally Jihyun Irizarry Lucy Ghoda Haris Ali Jeffery M. Trent Stephen Forman Yu-Hsuan Fu Ya-Huei Kuo Bin Zhang Guido Marcucci Source Type: research
